How big is the Asia Pacific Biologics Market?

The Asia Pacific Biologics Market is valued at US$ 1,01,590.5 Million in 2023, it is projected to reach US$ 4,17,082.9 Million by 2031.

What is the CAGR for Asia Pacific Biologics Market by (2023 - 2031)?

As per our report Asia Pacific Biologics Market, the market size is valued at US$ 1,01,590.5 Million in 2023, projecting it to reach US$ 4,17,082.9 Million by 2031. This translates to a CAGR of approximately 19.3% during the forecast period.

What segments are covered in this report?

The Asia Pacific Biologics Market report typically cover these key segments- 产品（单克隆抗体、疫苗、重组激素/蛋白质、细胞和基因治疗等）应用（癌症、传染病、自身免疫性疾病等）来源（哺乳动物和微生物）

What is the historic period, base year, and forecast period taken for Asia Pacific Biologics Market?

The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Biologics Market report: 2025-2031 2023 2021-2023

Who are the major players in Asia Pacific Biologics Market?

The Asia Pacific Biologics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include: AbbVie Inc ; Pfizer Inc ; Samsung Biologics Co Ltd ; ADMA Biologics, Inc. ; Wuxi Biologics Inc ; Catalent Inc ; AGC Biologics AS ; AstraZeneca Plc ; Amgen Inc ; Nitto Avecia ; Quality Assistance s.a.

Who should buy this report?

The Asia Pacific Biologics Market report is valuable for diverse stakeholders, including: Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns. Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies. Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry. Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies. Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market. Essentially, anyone involved in or considering involvement in the Asia Pacific Biologics Market value chain can benefit from the information contained in a comprehensive market report.

亚太生物制剂市场（主要地区、市场参与者、规模和份额）- 预测至 2031 年

2023 年亚太生物制剂市场价值为 1015.905 亿美元，预计到 2031 年将达到 4170.829 亿美元；预计 2023 年至 2031 年的复合年增长率为 19.3%。

发展中地区生物技术的发展推动亚太生物制剂市场

现代生物技术的许多应用都需要抗体，从基础研究到创新医学治疗方法。治疗性抗体的开发为治疗各种疾病开辟了新途径，展示了这些粒子的转化能力。抗体在诊断中也至关重要，因为它们为疾病识别提供了准确可靠的方法。政府日益增长的支持、不断增长的公私合作伙伴关系、不断变化的疾病状况以及不断增加的融资活动正在广泛提高亚太地区、南美洲和中美洲以及中东和非洲等地区生物技术产业的业绩。阿联酋、沙特阿拉伯、阿曼、马斯喀特、巴林、台湾、马来西亚、印度、中国大陆、新加坡和日本等国家和地区是生物技术行业利润丰厚的市场。生物技术、遗传学和细胞生物学的进步有助于发现多种用于靶向治疗的潜在疗法。生物技术是中国的战略性行业。“中国制造2025”计划强调支持高科技产品（包括创新药物）制造的研发能力。该计划引导中国制药公司瞄准目标领域，以刺激生物技术创新并增加出口。亚洲国家更注重将基因组学、蛋白质组学和生物标志物方面的进步用于诊断和治疗应用。因此，发展中地区生物技术行业的持续发展预计将在未来几年为生物制剂市场创造机遇。

亚太生物制剂市场概览

亚太地区的生物制剂市场分为中国、日本、印度、韩国、澳大利亚和亚太其他地区。该地区市场的增长得益于大量遗传性疾病患者以及各国政府不断增加的医疗研发投入。过去几年，中国民众对生物制剂益处的认识显著提高。此外，当地获得细胞系鉴定等广泛检测服务的渠道也不断扩大，许多生物制剂产品已从临床前开发阶段进入商业化阶段，这些都对市场的增长产生了积极的影响。近年来，科学家和卫生部门致力于推广如何有效利用生物制剂来研究和治疗疾病，以及开发药品和医疗器械。他们也在努力加深对先天性残疾发展机制的了解。三星生物制剂公司已与中国生物技术公司基因量子医疗签署合作协议，共同开发用于治疗非小细胞肺癌 (NSCLC)、三阴性乳腺癌 (TNBC) 和其他实体瘤的抗体-药物偶联物 (ADC)。

亚太生物制剂市场收入及预测至2031年（百万美元）

亚太生物制剂市场细分

亚太生物制剂市场分为产品、应用、来源、制造和国家。

根据产品，亚太生物制剂市场细分为单克隆抗体、疫苗、重组激素/蛋白质、细胞和基因治疗等。单克隆抗体细分市场在2023年占有最大的市场份额。

就应用而言，亚太生物制剂市场分为癌症、传染病、自身免疫性疾病等。癌症细分市场在2023年占有最大的市场份额。

按来源，亚太生物制剂市场分为哺乳动物和微生物。 2023 年，哺乳动物细分市场占有更大的市场份额。

根据制造方式，亚太生物制剂市场分为外包和内部制造。2023 年，外包细分市场占有更大的市场份额。

按国家/地区划分，亚太生物制剂市场分为中国、印度、日本、韩国、澳大利亚和亚太其他地区。2023 年，中国占据了亚太生物制剂市场的主导地位。

艾伯维公司 (AbbVie Inc)、辉瑞公司 (Pfizer Inc)、三星生物制剂有限公司 (Samsung Biologics Co Ltd)、ADMA Biologics, Inc.、无锡生物制剂有限公司 (Wuxi Biologics Inc)、康泰伦特公司 (Catalent Inc)、AGC Biologics AS、阿斯利康公司 (AstraZeneca Plc)、安进公司 (Amgen Inc)、Nitto Avecia 和 Quality Assistance sa 是亚太生物制剂市场的一些领先公司。

Asia Pacific Biologics Strategic Insights

Strategic insights for Asia Pacific Biologics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-biologics-market-strategic-framework.webp

Get more information on this report

Asia Pacific Biologics Report Scope

Report Attribute	Details
Market size in 2023	US$ 1,01,590.5 Million
Market Size by 2031	US$ 4,17,082.9 Million
Global CAGR (2023 - 2031)	19.3%
Historical Data	2025-2031
Forecast period	2021-2023
Segments Covered	By 产品（单克隆抗体、疫苗、重组激素/蛋白质、细胞和基因治疗等） By 应用（癌症、传染病、自身免疫性疾病等） By 来源（哺乳动物和微生物） By 制造（外包和内部）
Regions and Countries Covered	亚太地区（中国、日本、印度、澳大利亚、韩国、亚太其他地区）亚太地区（中国、日本、印度、澳大利亚、韩国、亚太其他地区）
Market leaders and key company profiles	AbbVie Inc Pfizer Inc Samsung Biologics Co Ltd ADMA Biologics, Inc. Wuxi Biologics Inc Catalent Inc AGC Biologics AS AstraZeneca Plc Amgen Inc Nitto Avecia

Get more information on this report

Asia Pacific Biologics Regional Insights

The regional scope of Asia Pacific Biologics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.